Accutest Biologics Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
- Paid Up Capital ₹ 1.00 M
- Company Age 12 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 30.00 Cr
- Satisfied Charges ₹ 131.86 Cr
- Revenue Growth -91.26%
- Profit Growth 372.12%
- Ebitda -241.29%
- Net Worth 32.99%
- Total Assets -45.44%
About Accutest Biologics
Accutest Biologics Private Limited (ABPL) is a Private Limited Indian Non-Government Company incorporated in India on 03 August 2012 and has a history of 12 years and six months. Its registered office is in Thane, Maharashtra, India.
The Corporate was formerly known as Quantimmune Solutions Private Limited. The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹30.00 Cr. The company has closed loans amounting to ₹131.86 Cr, as per Ministry of Corporate Affairs (MCA) records.
Ashvin George, Trinadha Yalamarti, and Suneel Regulla serve as directors at the Company.
Company Details
- Location
Thane, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U74900MH2012PTC234115
- Company No.
234115
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
03 Aug 2012
- Date of AGM
30 Dec 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Accutest Biologics?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Trinadha Yalamarti  | Nominee Director | 07-Oct-2022 | Current |
| Suneel Regulla | Nominee Director | 07-Oct-2022 | Current |
| Ashvin George | Nominee Director | 07-Oct-2022 | Current |
Financial Performance of Accutest Biologics.
Accutest Biologics Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 91.26% decrease. The company also saw a substantial improvement in profitability, with a 372.12% increase in profit. The company's net worth Soared by an impressive increase of 32.99%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Accutest Biologics?
In 2023, Accutest Biologics had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Plaeup Private LimitedAshvin George is a mutual person
Florintree Advisors Private LimitedAshvin George is a mutual person
Hansa Equity Partners LlpTrinadha Yalamarti and Suneel Regulla are mutual person
Charges (Loans)
₹30.00 Cr
₹131.86 Cr
Charges Breakdown by Lending Institutions
- Tata Capital Financial Services Limited : 30.00 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 03 Oct 2022 | Tata Capital Financial Services Limited | ₹30.00 Cr | Open |
| 05 Nov 2018 | Others | ₹112.04 Cr | Satisfied |
| 09 Jul 2014 | The Shamrao Vithal Co-Operative Bank Limited | ₹1.15 Cr | Satisfied |
| 07 Feb 2013 | The Shamrao Vithal Co-Operative Bank Limited | ₹18.67 Cr | Satisfied |
How Many Employees Work at Accutest Biologics?
Unlock and access historical data on people associated with Accutest Biologics, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Accutest Biologics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Accutest Biologics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
